Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
peptide
Biotech
With $30M, Oorja Bio breathes new life into fibrosis candidate
The biotech’s lead asset is ORJ-001, an activator of a receptor called β1 integrin that is key for maintaining lung structure and stability.
Darren Incorvaia
May 20, 2026 10:31am
Fierce Pharma
FDA advisory committee to discuss action on unapproved peptides
Apr 15, 2026 5:15pm
Syneron closes $150M round to support peptide platform
Apr 3, 2026 9:31am
Lisata reclaims China rights to solid tumor candidate from Qilu
Jan 27, 2026 10:12am
Cancer imaging company buys Lisata for ph. 2-stage tumor drug
Jan 21, 2026 9:20am
Mice given a brain protein lost weight without getting nauseous
Jul 24, 2025 7:00am